A5060428044- Adenosine and Purinergic Signaling
- Synthesis and Biological Evaluation
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Chemokine receptors and signaling
- Genetic diversity and population structure
- Rangeland and Wildlife Management
- Ecology and Vegetation Dynamics Studies
- Immune Cell Function and Interaction
University of California System
2005
Abstract T cells play a critical role in the control of cancer. The development immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed only subset patients, prompting research efforts to focus on strategies that target multiple inhibitory signals within tumor microenvironment (TME) limit evasion and improve patient outcomes. Adenosine emerged as potent suppressant TME, CD73 major enzyme...
Introduction: It has been demonstrated that myeloid derived suppressor cells (MDSCs) have a direct role in tumor immune evasion, and increased MDSCs are associated with reduced overall survival several types of cancer. Elevated levels circulating shown to correlate blunted response checkpoint blockade. secrete arginase, which depletes arginine, leading decreased T cell activity suppressed anti-tumor response. Here we will present the characterization AB474, highly potent small molecule...
Abstract Introduction: It has been demonstrated that myeloid derived suppressor cells (MDSCs) have a direct role in tumor immune evasion, and increased MDSCs are associated with reduced overall survival several types of cancer. Elevated levels circulating shown to correlate blunted response checkpoint blockade. secrete arginase, which depletes arginine, leading decreased T cell activity suppressed anti-tumor response. Here we will present the characterization AB474, highly potent small...
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Data from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
Supplementary Figure from Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule Inhibitor, Restores Immune Functionality Facilitates Antitumor Immunity
<div>Abstract<p>T cells play a critical role in the control of cancer. The development immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed only subset patients, prompting research efforts to focus on strategies that target multiple inhibitory signals within tumor microenvironment (TME) limit evasion and improve patient outcomes. Adenosine emerged as potent suppressant...
<div>Abstract<p>T cells play a critical role in the control of cancer. The development immune checkpoint blockers (ICB) aimed at enhancing antitumor T-cell responses has revolutionized cancer treatment. However, durable clinical benefit is observed only subset patients, prompting research efforts to focus on strategies that target multiple inhibitory signals within tumor microenvironment (TME) limit evasion and improve patient outcomes. Adenosine emerged as potent suppressant...